How Medicare Pays for Treating Multiple Related Conditions

Last updated 9 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

One patient can arrive with heart failure, chronic kidney disease, and diabetes—and leave with three separate care plans. Clinically, she has three deeply interconnected conditions that should be managed as a unified system. For billing, they are three separate diseases, each with its own diagnosis codes, treatment protocols, and reimbursement rules that may discourage the coordinated care she needs to stay alive.

Nearly 90 percent of U.S. adults have at least one risk factor for cardiovascular-kidney-metabolic syndrome—a recently defined condition where heart, kidney, and metabolic problems feed off each other. Yet only 12 percent of Americans have even heard of it.

The American Heart Association plans to release the first clinical guidelines focused on CKM syndrome in early 2026. That move will force Medicare administrators to confront an uncomfortable truth: the program’s payment structure was designed to reimburse diseases separately. It often creates financial incentives that work against the integrated care these patients need.

What CKM Syndrome Means

The heart pumps blood. The kidneys filter it and regulate blood pressure. The metabolic system—primarily liver and pancreas—controls how the body uses and stores energy. When any one of these systems starts failing, it creates a cascade that accelerates failure in the others.

A person with type 2 diabetes develops high blood pressure and elevated cholesterol. Those conditions damage the kidneys. Damaged kidneys can’t regulate blood pressure effectively, forcing the heart to work harder. The heart weakens. The weakened heart can’t pump blood efficiently through already-damaged vessels. Each condition makes the others worse. The spiral can end in heart attacks, strokes, dialysis, or death.

What makes CKM different from having “multiple chronic conditions” is that this isn’t coincidence. These aren’t separate diseases that happen to occur together. They’re manifestations of the same underlying dysfunction. Treating them as isolated problems is like trying to fix a car’s overheating engine by only addressing the temperature gauge.

Many of the newest medications—drugs that help multiple organs at once (like dapagliflozin and semaglutide)—work across multiple systems at the same time. A single drug can reduce the risk of kidney failure, heart failure hospitalization, and cardiovascular death all at once. But Medicare’s payment structure treats each of those benefits as belonging to a different specialty, different billing code, and different episode of care.

How the Payment System Reinforces Fragmentation

Sixty-eight percent of Americans incorrectly believed health conditions should be managed one at a time. Forty-two percent thought a healthy heart wouldn’t be affected by other organ systems.

These aren’t random misconceptions. They reflect how the healthcare system has organized itself for decades. When Medicare pays a cardiologist to manage heart failure and a nephrologist to manage kidney disease as separate episodes, it teaches everyone that this is how medicine works. Patients, clinicians, and administrators learn the same lesson. One condition, one specialist, one treatment plan.

The separation isn’t malicious. It made sense when these specialties developed. Medical knowledge was more limited, and the connections between organ systems were less understood. But the science has moved on. The payment system hasn’t. CMS has acknowledged the need for more coordinated care through value-based programs.

How Medicare Pays for This

Medicare divides coverage into parts that made administrative sense in 1965 but create chaos for modern chronic disease management. Part A covers hospital care. Part B covers physician services and outpatient care. Part D, added in 2006, covers prescription drugs. Each part has different rules, billing mechanisms, and coverage limits.

When a beneficiary with heart failure, kidney disease, and diabetes sees her primary care doctor, the clinician reviews all three conditions, adjusts medications that benefit multiple systems, discusses dietary changes that address sodium restriction for the heart and protein modification for the kidneys, and reinforces diabetes medication adherence.

The billing looks different. An Evaluation and Management code reflects the visit’s complexity, but documentation must specify which conditions were addressed. If the same medication provides benefit for multiple conditions, there’s no way to bill separately for addressing the same therapeutic decision three times. The visit gets reimbursed as a single episode. The complexity-based code reflects overall work, not the number of interconnected conditions managed.

This structure doesn’t reward integrated management. It creates no financial incentive to spend extra time integrating care across multiple conditions when payment is the same whether the clinician addresses one problem or five.

Then there are the medications. The drugs most central to CKM management—SGLT2 inhibitors, GLP-1 receptor agonists—fall under Part D, administered through private insurers. Each plan has its own list of covered drugs, cost levels, and approval processes. A cardiologist recommends an SGLT2 inhibitor for heart protection. A nephrologist recommends the same drug for kidney protection. An endocrinologist wants a GLP-1 for diabetes and cardiovascular risk reduction. All are medically sound. But the Part D plan responds primarily to cost, not clinical interconnectedness.

Someone might start the medication, then stop after a few months because the copayment—$50, $75, sometimes more—becomes unaffordable. Blood pressure climbs. Kidney function declines. Diabetes worsens. All preventable, but the payment system created a barrier the clinical system couldn’t overcome.

Care Coordination Benefits That Don’t Quite Coordinate

Chronic Care Management, introduced in 2015, pays practices for structured ongoing communication and coordination for patients with two or more chronic conditions. For the first 20 minutes per month, Medicare pays approximately $48.

Many practices find the model financially unsustainable. The documentation requirements are specific. The beneficiary must opt in and understand what they’re agreeing to. The reimbursement barely covers the staff time and infrastructure needed for coordination.

More fundamentally, these care coordination programs were designed with specific conditions in mind, not the integrated, multisystem approach CKM requires. A care coordinator might ensure the patient knows when to take medications and that all clinicians are aware of all prescriptions. But coordinating medication schedules isn’t the same as integrating an SGLT2 inhibitor prescription from the cardiologist with a GLP-1 recommendation from the endocrinologist while accounting for kidney function, blood pressure, and weight-loss goals at the same time.

That requires clinical expertise, and Medicare doesn’t pay for it. The current care-management benefit is largely built around communication and documentation.

Remote Patient Monitoring offers another piece of the puzzle. Beneficiaries use devices at home—weight scales for heart failure, blood pressure cuffs, continuous glucose monitors—and share data electronically with their care teams. Medicare pays for setup, device supply, data transmission, and clinical review time.

In practice, it requires interoperable devices and data platforms, patients willing and able to use technology, and provider staff time to monitor and respond to the data. For a person with CKM syndrome, effective RPM would mean integrating weight data, blood pressure readings, and glucose levels into a unified picture that informs treatment decisions across all three conditions. Most RPM implementations don’t reach that level of integration.

Coverage Limits That Block Treatment

CMS announced a new voluntary model to expand Part D coverage of GLP-1 medications for weight management. Some of the program’s most consequential barriers aren’t about payment structure. They’re about what the program won’t cover at all.

Obesity is both a risk factor for and a manifestation of CKM syndrome. The most recent clinical evidence supports intensive intervention. But Medicare Part D doesn’t cover GLP-1 receptor agonists when prescribed solely for weight loss in non-diabetic beneficiaries. Medicare law prevents coverage of these medications for that use.

A beneficiary with obesity, high blood pressure, and prediabetes—three of the four CKM components—could benefit enormously from a GLP-1. The medication would promote weight loss, lower blood pressure, improve metabolic parameters, and reduce cardiovascular risk. Multiple clinical trials prove this. But if the beneficiary doesn’t yet have diabetes, Part D won’t cover it for weight loss alone.

As of January 2026, the new model is still voluntary, and implementation details remain unclear.

Nutrition counseling presents similar problems. Diabetes Self-Management Training is covered for diabetic patients. Medical Nutrition Therapy is covered when provided by a registered dietitian. But coverage is limited in duration and may require prior authorization. A CKM patient ideally needs intensive nutrition counseling that addresses blood glucose control, kidney disease dietary restrictions (potassium, phosphorus), heart failure sodium limits, and weight loss at the same time. The system doesn’t accommodate an integrated nutrition assessment spanning all three conditions efficiently. Most beneficiaries get fragmented or incomplete dietary guidance.

Cardiac rehabilitation programs are covered for certain conditions—acute heart attack, post-surgery, heart failure. These programs combine supervised exercise, risk-factor modification, education, and psychological support. Research shows they significantly improve outcomes and reduce mortality. But a beneficiary with chronic kidney disease and heart failure might find themselves in a cardiac rehab program not optimally designed for renal constraints. Standard cardiac rehab might emphasize potassium-rich fruits as heart-healthy eating. It may not account for the fact that damaged kidneys can’t handle that potassium level. Two evidence-based recommendations can work against each other.

Value-Based Models That Might Help

The Medicare Shared Savings Program, which includes Accountable Care Organizations, is the largest payment model designed to align financial incentives with coordinated care and better outcomes. Groups of providers form an ACO and agree to manage care for a population of beneficiaries. They share savings if they reduce spending while maintaining or improving quality.

The theoretical advantage for CKM patients is significant. An ACO paid a fixed or prospectively determined amount to manage a person’s care has strong incentives to prevent hospitalizations, emergency visits, and disease progression. Fee-for-service providers get paid more when they deliver more services. ACOs make money by keeping patients healthy and away from expensive acute care.

In practice, results are mixed. Some ACOs have implemented integrated care programs and improved outcomes for people with heart failure, kidney disease, and diabetes. Many others have struggled to generate the organizational changes and infrastructure investments needed to manage CKM patients effectively.

The Kidney Care Choices model, tested in specific regions, aims to improve care for patients with chronic and end-stage kidney disease. It combines a fixed payment per patient, with bonuses for good outcomes, plus care coordination support. It’s intended to encourage dialysis providers, primary care practices, and nephrology specialists to work together more closely. But the model is new and geographically limited. Most beneficiaries with CKM syndrome don’t have access to it.

For rural beneficiaries, the challenges multiply. Rural areas often lack specialists—nephrologists, endocrinologists, cardiologists—meaning primary care physicians manage these patients with limited specialist consultation. CMS announced in 2026 that all 50 states would receive awards totaling $50 billion under the Rural Health Transformation Program, intended to strengthen rural healthcare infrastructure, expand access, strengthen the workforce, modernize facilities and technology, and support innovative care models.

Telehealth is expected to play a central role, allowing rural primary care providers to obtain real-time specialist consultation. Whether that translates into integrated CKM management or easier access to siloed specialty advice remains to be seen.

Medicare Advantage: Better or Different?

Approximately 28 million Medicare beneficiaries are enrolled in Medicare Advantage plans offered by private insurers. These plans provide the same coverage as traditional Medicare but with different provider networks, cost-sharing structures, and care management approaches.

MA plans might be better positioned than traditional Medicare to provide coordinated CKM care. They receive a fixed per-beneficiary payment and must provide benefits, creating stronger incentives to invest in preventive care and disease management that reduces future costs. Many MA plans have developed care management programs, employed care coordinators, and implemented predictive analytics to identify high-risk patients.

But MA plans also have more flexibility to determine which providers and drugs are covered, which services require prior authorization, and what cost-sharing patients must pay. That flexibility enables innovation. It also creates barriers.

When a beneficiary’s preferred cardiologist is out-of-network, the plan might direct them to an in-network cardiologist unfamiliar with their kidney or metabolic status. A recommended medication might require prior authorization, delaying treatment. An MA plan might refuse cardiac rehabilitation if its medical director determines the evidence doesn’t support it, even if the patient’s physician believes it would help.

Some MA plans have faced controversy regarding how they code diagnoses to maximize Medicare payments. Healthcare Dive has reported that some large MA insurers systematically captured higher numbers of diagnoses than other insurers, using hired nurses to visit patients’ homes, conduct health risk assessments, and identify unlisted conditions. This practice, sometimes called “upcoding,” can fall within regulations while raising risk scores (which determine how much Medicare pays) without necessarily improving care coordination or clinical management.

For CKM patients, the result can be paradoxical: coded as having more diagnoses than their physicians have documented, potentially inflating their risk profile without generating corresponding improvements in integrated care.

The Medication Access Problem

The drugs most central to optimal CKM management have become expensive. Under Medicare Part D, cost-sharing varies significantly by plan and by drug. Beneficiaries might face copayments from $5 to $50 per prescription depending on the tier. Others pay a percentage of the drug’s cost, which can exceed $100 per month even after the deductible is met.

For many beneficiaries, this cost-sharing is burdensome enough to affect medication adherence. Someone starts an SGLT2 inhibitor as recommended by their nephrologist, then discontinues after a few months because the copayment is unaffordable. Blood pressure rises. Kidney function declines. All preventable.

Real-world data consistently show cost-related non-adherence is highest among low-income seniors and dual-eligible beneficiaries—those with both Medicare and Medicaid. These are also the populations most likely to have CKM syndrome and most likely to benefit from intensive pharmacotherapy.

Prior authorization adds another barrier. Part D plans frequently require prior authorization for expensive medications, particularly GLP-1 receptor agonists and other newer drugs. Prior authorization is meant to ensure appropriate prescribing and control costs. Clinically, it delays necessary treatment.

Someone with elevated A1c, prediabetes, and obesity might benefit from immediate GLP-1 initiation. But if their plan requires prior authorization, there may be a delay of days or weeks while clinical staff review the request. From a systems perspective, it’s an administrative burden that can result in treatment never being initiated if the patient becomes discouraged.

Plans covering SGLT2 inhibitors for heart failure and kidney disease may not cover GLP-1 receptor agonists for weight loss. Plans may preferentially cover one SGLT2 inhibitor while placing a competing agent in a higher cost tier. That can discourage use of what may be more appropriate for a particular person’s clinical situation. These formulary restrictions fragment the ability of clinical teams to implement the integrated drug regimens CKM management requires.

The Silent Disease Problem

Many conditions in the CKM cluster don’t cause noticeable symptoms until they’re serious. Someone with elevated blood pressure, elevated cholesterol, and elevated blood glucose might feel healthy. Over months and years, these conditions damage the heart, kidneys, and blood vessels. The damage can look like a sudden crisis when the person experiences a heart attack or stroke or is discovered to have advanced kidney disease.

This lack of symptoms makes it difficult to motivate people to adhere to complex medication regimens, make dietary changes, and engage with care management programs. Someone who comes in feeling well may get prescribed multiple medications for conditions they don’t feel. They may also get referred to multiple specialists, a dietitian, and a care coordinator. Some patients perceive this as overtreatment rather than appropriate prevention.

Within a fee-for-service model, providers have limited time for patient education and engagement and limited financial incentive to invest in understanding the patient’s health beliefs, cultural background, and social circumstances. Those factors can affect willingness to engage with the care plan. Many CKM interventions are implemented by motivated clinicians and motivated patients, but a significant proportion of at-risk individuals don’t receive the intensive engagement optimal outcomes require.

According to kidney health experts, clinical success depends on patient engagement, and the challenge lies in treating risks that cause no symptoms while finding the right integration of nephrology, cardiology, and primary care. The transition from small-scale, multidisciplinary successes in integrated care centers to national scalability remains a hurdle.

What the 2026 Guidelines Could Change

The American Heart Association’s planned release of the first clinical guidelines focused on CKM syndrome in early 2026 represents a potential inflection point. Historically, when major medical societies release clinical practice guidelines, those guidelines influence physician behavior and medical education. Increasingly, they also influence payer policies, including Medicare coverage decisions and quality measures.

The guidelines have potential to shift Medicare’s approach in several ways. They may lead to changes in quality measurement and pay-for-performance initiatives. Currently, Medicare’s quality measures for chronic disease management tend to be disease-specific, including measures for hypertension control, diabetes control, and heart failure readmission rates. A CKM framework suggests integrated quality measures tracking outcomes across multiple related conditions might be more appropriate.

Rather than measuring the percentage of diabetic beneficiaries whose A1c is at goal, an integrated measure might assess the percentage of CKM patients with appropriate control of blood pressure, lipids, glucose, and protein in urine (a sign of kidney damage) at the same time.

The guidelines may influence Medicare’s coverage decisions. If the AHA recommends specific drug combinations, care coordination approaches, or screening tests for CKM patients, Medicare may face pressure to adjust coverage policies to align. This could potentially lead to expanded coverage of GLP-1 receptor agonists beyond current indications, broader coverage of continuous glucose monitoring or other remote monitoring technologies, or faster implementation of care coordination benefits designed for CKM patients.

The guidelines may accelerate Medicare’s investment in new payment models that align with CKM principles. CMS has demonstrated willingness to experiment with alternative payment arrangements through its Innovation Center. High-profile endorsement of integrated CKM care from the American Heart Association could provide political and clinical momentum for expanding models to more beneficiaries and broader geographic areas.

Clinical guidelines are recommendations, not mandates. CMS must balance clinical evidence with cost considerations and feasibility of implementation. It must also work within limitations on what Medicare can cover. Medicare law prevents coverage of GLP-1 receptor agonists for weight loss in non-diabetic individuals, and that can’t be changed through guidelines alone. The fragmentation of benefits across Part A, B, and D is embedded in law. Addressing it would require Congressional action.

The Equity Dimension

The inaugural JACC Cardiovascular Statistics 2026 report documents “persistent disparities by race, geography and socioeconomic status” across all cardiovascular risk factors and conditions. Black Americans are approximately four times more likely than white Americans to have kidney failure. Hispanic and Latin American individuals are approximately two times more likely.

These disparities reflect a complex interplay of factors including genes, pollution, whether people can see doctors, whether doctors treat them well, and racism in healthcare.

For beneficiaries, disparities in CKM care show up in multiple ways. Rural beneficiaries face challenges accessing specialists necessary for integrated management. Black and Hispanic beneficiaries face systematic barriers in accessing high-quality primary and specialty care. When they do access care, they often receive lower-quality treatment. Medicare Advantage plans serving predominantly lower-income populations often provide less care coordination infrastructure.

Boehringer Ingelheim and CommonSpirit Health announced in January 2026 a strategic partnership to improve CKM screening and diagnosis in vulnerable populations through the Community-led Approach to Increasing CKM Awareness program in Chattanooga and Omaha. The initiative acknowledges that “some populations are at higher risk for kidney disease” and “face more barriers to accessing primary care.”

For Medicare policy, the equity implications are clear: payment models that work for affluent, educated populations with reliable transportation and stable housing may not work for lower-income, rural, or minority populations facing additional social determinants of health challenges. Effective integration of CKM care for these populations will require not only reforming Medicare’s payment structure. It will also require investing in community health workers, transportation assistance, food support, and other social services that address root causes of health disparities.

The Role of Light Physical Activity

A landmark study published in January 2026 found that light-intensity physical activity—even from common everyday tasks like loading the dishwasher or folding laundry—was associated with substantial reductions in mortality among adults with CKM syndrome. Among more than 7,000 adults in the study, 3 to 5 hours daily of light physical activity was linked to as much as a 20 percent lower relative risk of mortality over 14 years.

This finding suggests encouraging and facilitating physical activity for CKM patients may be among the most cost-effective interventions available. Yet Medicare’s current payment structure provides limited reimbursement for physical activity counseling, exercise programs, or support services including community fitness memberships and transportation to exercise programs.

Cardiac rehabilitation programs, which include supervised exercise, are covered for certain patient populations. Some MA plans have begun offering supplemental benefits including fitness program memberships or other activity support. But traditional fee-for-service Medicare coverage remains limited.

The recognition of light-intensity activity benefits is important for CKM patients who are elderly, obese, or have advanced kidney disease. These populations often can’t tolerate high-intensity exercise and may have been discouraged from physical activity out of safety concerns. If light-intensity activity provides substantial mortality benefit, then enabling and encouraging such activity through counseling, community programs, and removal of barriers represents an opportunity for significant population health impact at relatively low cost.

What Needs to Change

Current Medicare payment and coverage policies were not designed to manage conditions like CKM syndrome that span multiple organ systems and require integrated, coordinated care. The fragmentation of benefits across Part A, Part B, and Part D creates barriers. So does the continued reliance on fee-for-service payment. The separation of physician payment from payment for care coordination, education, and behavioral health services also matters. Another barrier is the continued use of disease-specific rather than integrated quality measures.

CMS can expand care coordination benefits designed for CKM patients. Chronic care management, behavioral health integration, and payments for managing a patient’s main health condition exist but are underutilized, inadequately reimbursed, and not optimized for integrated multisystem disease management. CMS can create a CKM care management benefit with higher reimbursement rates and streamlined eligibility and documentation requirements. Payment amounts should be sufficient to support multidisciplinary care team involvement, including physicians and nurses, plus dietitians, behavioral health specialists, and care coordinators with training in CKM management.

CMS can adjust coverage policy for key medications. The legal barrier to covering GLP-1 receptor agonists for weight loss in non-diabetic beneficiaries should be revisited and reformed, given strong evidence for cardiometabolic benefits and obesity’s role in driving CKM syndrome. The voluntary model announced by CMS for expanding GLP-1 coverage should be made permanent and expanded to reach all beneficiaries. CMS can work to reduce cost-sharing for key CKM medications through Part D redesign placing cardiometabolic agents in lower cost-sharing tiers.

CMS can invest in value-based care models that align payment with integrated outcomes. Medicare’s shared savings program for coordinated care groups should be modified to provide stronger incentives for integrated CKM care, including quality measures focused on CKM outcomes, additional care management payment, and technical assistance for building integrated care delivery infrastructure. Innovation models focused on CKM should be expanded beyond current kidney-disease-specific initiatives to encompass the full CKM framework.

CMS can prioritize investment in rural health and technology to expand access to specialists and integrated care in underserved communities. The Rural Health Transformation Program represents an important opportunity. CMS should ensure funding supports not only telehealth infrastructure but also training of primary care providers in integrated CKM care and community health workers who can provide patient education and engagement.

CMS can reform quality measurement to align with CKM science. The current disease-specific measurement framework should be complemented by integrated CKM measures that assess control of multiple risk factors at the same time and track outcomes reflecting how heart, kidney, and metabolism problems make each other worse.

The Science Has Moved On

The emergence of cardiovascular-kidney-metabolic syndrome as a unified clinical framework represents a significant advancement in medical science’s understanding of how interconnected chronic diseases progress and how they should be treated. The American Heart Association’s planned 2026 guidelines will likely accelerate integration of this framework into medical practice and training.

But translation of clinical science into real-world improvements in patient outcomes depends on whether healthcare payment systems align with clinical evidence. Currently, they don’t.

Medicare’s fragmented benefit structure and fee-for-service payment incentives create barriers. Disease-specific quality measures and coverage limitations add more. Clinicians can recognize the science of CKM and want to practice integrated, coordinated care. But the payment system provides limited support and sometimes disincentives for doing so.

Many beneficiaries with CKM syndrome receive good care when they encounter motivated and well-resourced providers and health systems. But care is suboptimal in terms of integration and coordination for a large proportion of the population.

For the nearly 90 percent of Americans with risk factors for CKM syndrome, and for the millions of beneficiaries living with multiple related chronic conditions, how Medicare pays for treating these conditions will shape health outcomes and financial security for years to come. The payment system needs to catch up to the science.